1579-78-8

Basic information

• Product Name: 3-(4-Fluorophenoxy)propionic acid
• Synonyms: 3-(4-FLUOROPHENOXY)PROPANOIC ACID;3-(4'-FLUOROPHENOXY)PROPIONIC ACID;3-(4-FLUOROPHENOXY)PROPIONIC ACID;BUTTPARK 21\07-85;IFLAB-BB F1924-0040;RARECHEM AL BO 1453;3-(4-Fluorophenoxy)propionic acid 97%;3-(4-Fluorophenoxy)propionicacid97%
• CAS NO: 1579-78-8
• Molecular Formula: C₉H₉FO₃
• Molecular Weight: 184.16
• EINECS: 216-424-6
• Product Categories: Aliphatics;Carboxylic Acids;Carboxylic Acids;C9;Carbonyl Compounds
• Mol File: 1579-78-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 83-85 °C(lit.)
• Boiling Point: 287.7 °C at 760 mmHg
• Flash Point: 127.8 °C
• Appearance: /
• Density: 1.267 g/cm³
• PKA: 4.82±0.10(Predicted)
• CAS DataBase Reference: 3-(4-Fluorophenoxy)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Fluorophenoxy)propionic acid(1579-78-8)
• EPA Substance Registry System: 3-(4-Fluorophenoxy)propionic acid(1579-78-8)

Safety Data

• Hazard Codes: C,Xi
• Statements: 36/37/38
• Safety Statements: 26-26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1579-78-8(Hazardous Substances Data)

Usage

Uses

3-(4-Fluorophenoxy)propionic acid may be used as one of the reactants for the synthesis of 2,3-dihydro-6-fluoro-4H-1-benzopyran-4-one.

General Description

3-(4-Fluorophenoxy)propionic acid can be synthesized by employing 3-(4-fluorophenoxy)propanenitrile as a starting reagent.

Upstream product

• 104413-57-2 3-(4-fluorophenoxy)-1-propanol 
• 590-92-1 3-Bromopropionic acid 
• 371-41-5 4-Fluorophenol 
• 371-40-4 4-fluoroaniline 
• 85169-02-4 3-(4-fluoro-phenoxy)propionitrile 
• 107-94-8 chloropropionic acid 

Downstream Products

• 66892-34-0 6-fluoro-4-chromanone 
• 113209-68-0 3,4-dihydro-7-fluoro-2H-1-benzopyran-4-one 
• 1093091-90-7 2-chloro-6-(4-{3-[(4-fluorophenyl)oxy]propanoyl}-1-piperazinyl)benzonitrile 
• 1093091-89-4 5-chloro-2-(4-{3-[(4-fluorophenyl)oxy]propanoyl}-1-piperazinyl)benzonitrile 
• 1093092-11-5 1-{3-[(4-fluorophenyl)oxy]propanoyl}piperazine 
• 223136-61-6 O-(p-toluenesulfonyl)-3-(4-fluorophenoxy)propanol 
• 143922-25-2 4-amino-1-(3-(4-fluorophenoxy)propyl)piperidine 
• 223136-62-7 N-Acetyl-1-(3-(4-fluorophenoxy)propyl)-4-aminopiperidine 
• 1531634-71-5 (±)-(4-chloro-2-{5-[3-(4-fluoro-phenoxy)-propionyl]-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-4-yl}-phenoxy)-acetic acid 
• 1445884-77-4 (3-{5-fluoro-2-[3-(4-fluorophenoxy)propionyl]-1,2,3,4-tetrahydroisoquinolin-8-yl}-4-methoxyphenyl)acetic acid 
• 1421435-11-1 2-[2-(6-fluorochroman-4-ylidene)hydrazinyl]-5-phenylthiazole 
• 82070-01-7 6-fluorochroman 
• 1245316-24-8 dimethyl 2-(3-(4-fluorophenoxy)propanamido)malonate 
• 1245317-11-6 1-(4-(5-amino-2-(2-(4-fluorophenoxy)ethyl)thiazolo[5,4-d]pyrimidin-7-yl)piperazin-1-yl)-2-(4-chlorophenoxy)ethanone 

Relevant articles and documents

Acid activated montmorillonite K-10 mediated intramolecular acylation: Simple and convenient synthesis of 4-chromanones

3-Aryloxyproionic acids undergo intramolecular cyclization in the presence of AA.Mont.K-10 in toluene under reflux for 30–45 min in good to excellent yields. Phenyl ring bearing various substituents at the ortho, meta, para positions undergo this cyclization reaction. This method involves simple work up and amenable for large scale preparations. The heterogeneous acid treated catalyst can be regenerated and used for up to three cycles with minimum loss of activity.

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.

Novel thiazolidine derivatives

The invention relates to with novel thiazolidine derivatives of the formula STR1 wherein X is methylene, oxygen or sulfur; R1 is halogen; R2 is hydrogen, nitro, cyano, OR3 or NHR3 ; or R1 and R2 both simultaneously are hydrogen or nitro; R3 is hydrogen, alkyl, acyl, --CO--OR4 or --CO--NHR4 ; and R4 is alkyl, unsubstituted or substituted aryl or aralkyl, and their salts with physiologically compatible cations. The compounds of formula I are useful in the treatment of metabolic disorders.